ThermoFisherScientific - Custom and Bulks
Pharma Focus Europe
Worldwide Clinical Trials - Oncology

Gerresheimer Initiates Groundbreaking for New Facility in Querétaro, Supported by a $109.28 Million (100 Million Euro) Investment

Introduction:

The expansion focuses on increasing production capacities for "ready-to-fill" (RTF) syringes for the North American market.

Features:

The 7,500 m² production building is geared towards enhancing manufacturing capacity by producing several hundred million RTF syringes annually.

The project is expected to create approximately 270 new jobs at the Querétaro plant, currently employing around 1,000 people.

Gerresheimer plans to incorporate the latest automation and quality assurance technology to ensure the production of high-quality pre-fillable glass syringes suitable for injectable biopharmaceuticals.

The expansion is aligned with market demands and advancements in pharmaceuticals, particularly in the treatment of obesity with GLP-1-based drugs.

Syringe preparation processes, including washing and packaging, will adhere to ISO 8 to ISO 6 class clean rooms, emphasizing a commitment to quality and precision.

The project signifies Gerresheimer's dedication to growth, technological advancement, and economic development in the Querétaro region.

The state-of-the-art facility, scheduled for completion by mid-2024, will house 10 glass-forming machines, needle assembly lines, and RTF production lines.

Production is anticipated to commence in the second quarter of 2025, contributing to the company's position as a key player in the pharmaceutical industry.

Specifications:

Name: Gerresheimer

Type: Expansion

Year: 2025

magazine-slider-img
Pall+CytivaAdvertisement
patheon - Mastering API production at every scale7th Pharma Packaging and Labelling Forum 2024Future Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing Pharma